| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-049 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 二、议案审议情况 本次会议是否有否决议案：无 一、会议召开和出席情况 (一) 股东会召开的时间：2025 年 5 月 29 日 (二) 股东会召开的地点：湖南省长沙市金洲大道 68 号益丰医药物流园三楼 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 342 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 942,399,960 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 77.7290 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本 ...

关于益丰大药房连锁股份有限公司 2024年年度股东会的 法律意见书 二O二五年五月 致：益丰大药房连锁股份有限公司 （三）本所律师未授权任何单位或个人对本法律意见书作任何解释或说明。 为发表本所律师见证意见，本所律师依法审核了公司提供的下列资料： 1、刊登在中国证券监督管理委员会（以下简称"中国证监会"）指定媒体巨 潮资讯站（http://www.cninfo.com.cn/）的与本次股东会有关的通知等公告事项； 2、出席会议的股东或其代理人的身份证明文件、持股证明文件、授权委托书 等； 湖南启元律师事务所（以下简称"本所"）接受益丰大药房连锁股份有限公 司（以下简称"公司"）的委托，指派律师出席了公司 2024 年年度股东会（以下 简称"本次股东会"），对本次股东会的召集和召开程序、出席会议人员及召集 人的资格、表决程序和表决结果的合法有效性进行现场律师见证，并发表本法律 意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》、《上市公司股东会规则》（以下简称"《股东会规则》"） 等我国现行法律、法规、规范性文件以及《益丰大药房连锁股份有限公司章程》 （以下简称" ...

Core Viewpoint - The China Securities Index for Food and Major Consumer Goods Retail has shown a decline in performance over various time frames, indicating potential challenges in the sector [1][2]. Group 1: Index Performance - The China Securities Index for Food and Major Consumer Goods Retail is currently at 9719.75 points, having decreased by 0.13% over the past month, 2.88% over the past three months, and 4.47% year-to-date [1]. - The index is based on a sample of listed companies in the food and drug retail sector, reflecting the overall performance of these securities [1]. Group 2: Index Composition - The top ten weighted companies in the index include Yonghui Supermarket (6.96%), Digital China (6.48%), Shanghai Pharmaceuticals (6.14%), Yifeng Pharmacy (4.97%), and others, indicating a concentration in a few key players [1]. - The index is primarily composed of companies listed on the Shanghai Stock Exchange (55.91%) and Shenzhen Stock Exchange (44.09%) [1]. Group 3: Industry Breakdown - The industry composition of the index shows that pharmaceutical commerce accounts for 48.65%, specialized retail for 19.84%, department stores for 16.99%, and supermarkets and convenience stores for 14.52% [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2].

Core Viewpoint - The company, Yifeng Pharmacy Chain Co., Ltd., is set to hold an annual performance briefing for 2024 and the first quarter of 2025 on June 3, 2025, to provide insights into its operational results and financial status [2][3][4]. Group 1: Performance Briefing Details - The performance briefing will take place on June 3, 2025, from 15:00 to 16:00 [4]. - The event will be held at the Shanghai Stock Exchange Roadshow Center and will utilize video and online interaction for communication [4][5]. - Investors can submit questions for the briefing from May 27 to June 2, 2025, through the Roadshow Center website or via the company's email [2][5]. Group 2: Management Participation - Key participants in the briefing will include the Chairman and CEO, Mr. Gao Yi, the Financial Officer, Mr. Wang Yonghui, the Board Secretary, Mr. Fan Wei, and the Independent Director, Mr. Huang Chunan [4]. Group 3: Shareholding and Reduction Plan - Prior to the reduction plan, the Executive President, Mr. Gao Youcheng, held 201,600 shares, representing 0.0166% of the total share capital, while the Assistant President, Mr. Yan Jun, held 99,600 shares, representing 0.0082% [8]. - The reduction plan was disclosed on January 24, 2025, with a maximum reduction of 75,300 shares planned, which was successfully executed within the specified timeframe [9][10].

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-048 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 高级管理人员减持计划时间届满暨 减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 高级管理人员的基本情况 本次减持股份计划实施前，益丰大药房连锁股份有限公司（以下简称"公司"） 执行总裁高佑成先生持有公司股份 201,600 股（全部为无限售流通股），占公司 总股本比例0.0166%；公司助理总裁颜俊先生持有公司股份99,600股（其中16,200 股为有限售流通股，83,400 股无限售流通股），占公司总股本比例 0.0082%。上 述股份来源均为限制性股票激励计划授予及资本公积金转增股本取得。 减持计划的实施结果情况 1 | 股东身份 | 控股股东、实控人及一致行动人 | | □是 | √否 | | --- | --- | --- | --- | --- | | | 直 ...

| | | 益丰大药房连锁股份有限公司 关于召开2024年度暨2025年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 06 月 03 日(星期二)下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频和网络互动 投资者可于 2025 年 05 月 27 日(星期二) 至 06 月 02 日(星期一)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@yfdyf.com 进 行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 一、 说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2024 年年度与 2025年第一季度经营成果及财务指标的具体情况与投资者进行互动交流和沟通， 在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说 ...

益丰药房（603939）公告，公司执行总裁高佑成和助理总裁颜俊的减持计划已于2025年5月23日届满。 高佑成先生减持50400股，减持价格区间为24.32～24.32元/股，减持总金额为122.57万元，减持比例为 0.0042%。颜俊先生减持22900股，减持价格区间为25.02～25.02元/股，减持总金额为57.3万元，减持比 例为0.0019%。减持计划与实际减持情况一致，未达到最低减持数量，未提前终止减持计划。 ...

Core Viewpoint - The competition among major platforms like Ele.me, JD.com, and Meituan in the food delivery sector has expanded into the pharmaceutical category, leading to a significant rise in the instant retail of medicines, with platforms investing in traffic resources, supply chains, and innovative marketing strategies [1][4]. Group 1: Market Dynamics - The instant retail of pharmaceuticals is experiencing rapid growth, becoming a crucial part of the outpatient pharmaceutical retail market [1][4]. - JD Health's "Buy Medicine in Seconds" feature has seen a threefold increase in order volume due to enhanced traffic resources [4][6]. - The instant retail sector is evolving from high-frequency to low-frequency demand, now covering a full range of categories, including pharmaceuticals [5][6]. Group 2: Platform Strategies - JD.com has prominently featured "24h Delivery of Medicines" on its app, enhancing visibility and traffic for its instant retail services [3][4]. - Meituan has launched its instant retail brand "Meituan Flash Purchase," further intensifying competition in the pharmaceutical retail space [4][6]. - Taobao's instant retail service has been upgraded to "Taobao Flash Purchase," which includes a significant category for purchasing medicines [3][4]. Group 3: Industry Trends - The transformation of physical pharmacies is driving the adoption of instant retail, as many pharmacies are closing, leading to a competitive environment where digital solutions are essential [7][8]. - The integration of online medical services with instant retail is creating a comprehensive service model for users, enhancing the purchasing experience [7][8]. - The collaboration among platforms, pharmaceutical companies, and pharmacies is deepening, allowing for more effective marketing and sales strategies [8][10]. Group 4: Financial Performance - One Heart Hall's new retail segment saw a 47.6% year-on-year increase in revenue, with the O2O instant retail channel contributing 78.2% [15][16]. - Yifeng Pharmacy reported online sales of 2.127 billion yuan in 2024, with 1.721 billion yuan coming from O2O, accounting for 80.9% of total online sales [16][17]. - The overall trend indicates that if online medical insurance is fully opened, the share of instant retail in physical pharmacies could rise to 32.1% by 2030 [16][17]. Group 5: Future Outlook - The competition for instant retail in pharmaceuticals among major platforms is expected to continue, with Douyin's unique position in social media marketing presenting both opportunities and challenges [18]. - The penetration of instant retail in lower-tier markets is anticipated to grow, making it a significant growth driver in the outpatient pharmaceutical retail market [18].

Core Viewpoint - The retail pharmacy industry in China is undergoing significant challenges, with a trend of store closures and a shift from aggressive expansion to a focus on quality and efficiency [3][4][10]. Group 1: Store Closures and Industry Trends - Major retail pharmacy chains, including Lao Bai Xing, Yi Feng Pharmacy, and Yi Xin Tang, have reported a continued strategy of closing underperforming stores while slowing down expansion efforts [3][4]. - In Q1 2025, Lao Bai Xing and Shu Yu Ping Min closed 161 and 86 stores respectively, while Yi Feng Pharmacy opened 94 stores but closed 84 [3][7]. - The overall closure rate in the retail pharmacy sector reached 5.7% in 2024, with over 39,000 stores shutting down [4][11]. Group 2: Financial Performance - Yi Feng Pharmacy reported Q1 2025 revenue of 600.9 million yuan, a year-on-year increase of 0.64%, while its net profit grew by 10.51% [7]. - In contrast, Lao Bai Xing, Yi Xin Tang, and Jian Zhi Jia experienced revenue declines of 1.88%, 6.53%, and 0.85% respectively in Q1 2025 [7][8]. - The financial performance of many listed pharmacy chains has shown a decline in both revenue and profit, indicating a challenging market environment [6][8]. Group 3: Market Dynamics and Future Outlook - The retail pharmacy industry is experiencing a consolidation phase, driven by increased market concentration and regulatory pressures [10][14]. - The shift from rapid expansion to a focus on closing unprofitable stores and improving operational efficiency is becoming a new trend in the industry [10][12]. - Companies are exploring new retail models and diversifying their offerings to adapt to changing market conditions, with some focusing on integrating online and offline sales [14][15].

Core Viewpoint - The retail pharmacy industry in China is facing significant challenges, leading to a wave of store closures and a shift in focus from rapid expansion to improving operational efficiency and quality [1][6][8]. Group 1: Store Closures and Expansion Strategies - Major retail pharmacy chains, including Lao Bai Xing, Yi Feng Pharmacy, and Yi Xin Tang, are continuing to close underperforming stores while slowing down their expansion efforts [1][4]. - In Q1 2025, Lao Bai Xing closed 161 stores and opened 24, while Yi Feng Pharmacy opened 94 stores (26 self-built and 68 franchises) but closed 84 [1][4]. - The overall closure rate for retail pharmacies reached 5.7% in 2024, with over 39,000 stores shutting down [1][6]. Group 2: Financial Performance - Financial reports for Q1 2025 show a mixed performance among major chains, with Lao Bai Xing, Yi Xin Tang, and Jian Zhi Jia experiencing revenue and profit declines [3][4]. - Yi Feng Pharmacy reported a revenue of 6.009 billion yuan, up 0.64% year-on-year, and a net profit of 449 million yuan, up 10.51% [3][4]. - Dazheng Lin achieved a revenue of 6.956 billion yuan, up 3.02%, and a net profit of 460 million yuan, up 15.45% [3][4]. Group 3: Industry Trends and Challenges - The retail pharmacy sector is undergoing a deep transformation, moving from aggressive expansion to a focus on quality and efficiency due to market saturation and increased regulatory scrutiny [6][8]. - The number of pharmacies in China increased from 524,000 in 2019 to 667,000 in 2023, leading to structural oversupply [8][9]. - Industry experts predict that around 20% of small pharmacies may be eliminated, further increasing market concentration [8]. Group 4: New Retail Strategies - Leading chains are integrating online and offline operations to adapt to changing market dynamics, with Yi Feng Pharmacy reporting significant online sales growth [9][10]. - Dazheng Lin is focusing on building a prescription transfer system and enhancing professional service capabilities to differentiate itself in a competitive landscape [9][10]. - Yi Xin Tang is exploring diversification into non-pharmaceutical products and new business models, such as combining pharmacies with convenience stores [10].